{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F0d5291df-0fa8-45fc-93ed-aaddd9186ca7","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer \u2014 Part 3 of a Special 3-Part Edition\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/0d5291df-0fa8-45fc-93ed-aaddd9186ca7\"></iframe>","title":"Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer \u2014 Part 3 of a Special 3-Part Edition","description":"Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field.","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/97635d70-f91b-4542-ac9e-4ad77eab0c7d/HDx77o9GuXjm3JsutW_azrxg.png"}